Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Similar articles for PubMed (Select 24878431)

1.

Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia.

Koola MM, Buchanan RW, Pillai A, Aitchison KJ, Weinberger DR, Aaronson ST, Dickerson FB.

Schizophr Res. 2014 Aug;157(1-3):84-9. doi: 10.1016/j.schres.2014.04.037. Epub 2014 May 28. Review.

2.

Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.

Grossberg GT, Edwards KR, Zhao Q.

J Clin Pharmacol. 2006 Jul;46(7 Suppl 1):17S-26S. Review.

PMID:
16809811
3.

A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI.

Peters O, Lorenz D, Fesche A, Schmidtke K, Hüll M, Perneczky R, Rüther E, Möller HJ, Jessen F, Maier W, Kornhuber J, Jahn H, Luckhaus C, Gertz HJ, Schröder J, Pantel J, Teipel S, Wellek S, Frölich L, Heuser I.

J Nutr Health Aging. 2012;16(6):544-8.

PMID:
22659994
4.
5.

Targeting alpha-7 nicotinic neurotransmission in schizophrenia: a novel agonist strategy.

Deutsch SI, Schwartz BL, Schooler NR, Brown CH, Rosse RB, Rosse SM.

Schizophr Res. 2013 Aug;148(1-3):138-44. doi: 10.1016/j.schres.2013.05.023. Epub 2013 Jun 13.

6.

Galantamine potentiates the neuroprotective effect of memantine against NMDA-induced excitotoxicity.

Lopes JP, Tarozzo G, Reggiani A, Piomelli D, Cavalli A.

Brain Behav. 2013 Mar;3(2):67-74. doi: 10.1002/brb3.118. Epub 2013 Jan 11.

7.

What is the rationale for new treatment strategies in Alzheimer's disease?

Rogawski MA.

CNS Spectr. 2004 Jul;9(7 Suppl 5):6-12.

PMID:
15241294
8.

The effects of galantamine on psychopathology in chronic stable schizophrenia.

Conley RR, Boggs DL, Kelly DL, McMahon RP, Dickinson D, Feldman S, Ball MP, Buchanan RW.

Clin Neuropharmacol. 2009 Mar-Apr;32(2):69-74. doi: 10.1097/WNF.0B013E31816F2795.

9.

Galantamine for Alzheimer's disease and mild cognitive impairment.

Loy C, Schneider L.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD001747. Review.

PMID:
16437436
11.

Galantamine for vascular cognitive impairment.

Birks J, Craig D.

Cochrane Database Syst Rev. 2006 Jan 25;4:CD004746. doi: 10.1002/14651858.CD004746.pub2. Review.

PMID:
23862185
12.

Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia.

Buchanan RW, Freedman R, Javitt DC, Abi-Dargham A, Lieberman JA.

Schizophr Bull. 2007 Sep;33(5):1120-30. Epub 2007 Jul 19. Review.

13.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2002;(3):CD001747. Review. Update in: Cochrane Database Syst Rev. 2004;(4):CD001747.

PMID:
12137632
14.

Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia.

Kelly DL, McMahon RP, Weiner E, Boggs DL, Dickinson D, Conley RR, Buchanan RW.

Schizophr Res. 2008 Aug;103(1-3):161-8. doi: 10.1016/j.schres.2008.04.027. Epub 2008 Jun 11.

15.

Galantamine for vascular cognitive impairment.

Craig D, Birks J.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004746. Review. Update in: Cochrane Database Syst Rev. 2013;4:CD004746.

PMID:
16437493
16.

Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.

Tan CC, Yu JT, Wang HF, Tan MS, Meng XF, Wang C, Jiang T, Zhu XC, Tan L.

J Alzheimers Dis. 2014;41(2):615-31. doi: 10.3233/JAD-132690. Review.

PMID:
24662102
17.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2001;(4):CD001747. Review. Update in: Cochrane Database Syst Rev. 2002;(3):CD001747.

PMID:
11687119
18.

In vitro galantamine-memantine co-application: mechanism of beneficial action.

Zhao X, Marszalec W, Toth PT, Huang J, Yeh JZ, Narahashi T.

Neuropharmacology. 2006 Dec;51(7-8):1181-91. Epub 2006 Sep 29.

PMID:
17011596
19.

High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia.

Dyer MA, Freudenreich O, Culhane MA, Pachas GN, Deckersbach T, Murphy E, Goff DC, Evins AE.

Schizophr Res. 2008 Jul;102(1-3):88-95. doi: 10.1016/j.schres.2007.12.491. Epub 2008 Mar 5.

20.

Effective pharmacological management of Alzheimer's disease.

Atri A.

Am J Manag Care. 2011 Nov;17 Suppl 13:S346-55. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk